Replimune Group (NASDAQ:REPL) Reaches New 1-Year High – Still a Buy?

Replimune Group, Inc. (NASDAQ:REPL) shares reached a new 52-week high during trading on Thursday . The company traded as high as $13.90 and last traded at $12.86, with a volume of 6196951 shares changing hands. The stock had previously closed at $11.83.

Key Stories Impacting Replimune Group

Here are the key news stories impacting Replimune Group this week:

• Positive Sentiment: The FDA granted accelerated approval to Tudriqev (RP1/vusolimogene oderparepvec) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma whose disease progressed after an anti-PD-1-based treatment. The approval gives Replimune its first marketed product and creates a potential commercial revenue opportunity. Reuters FDA approval article
• Positive Sentiment: JPMorgan raised its price target on Replimune from $17 to $20 and maintained an “overweight” rating, indicating analysts see substantial upside from the company’s newly commercialized therapy. Benzinga price target report
• Positive Sentiment: Call-option activity was unusually high, with investors purchasing 25,580 calls—nearly double the average daily volume—suggesting increased speculative bullish positioning, although options activity does not guarantee further gains.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on REPL. Wolfe Research upgraded Replimune Group to an “outperform” rating in a research report on Tuesday. Cantor Fitzgerald downgraded Replimune Group from an “overweight” rating to a “hold” rating in a report on Monday, April 13th. HC Wainwright reiterated a “sell” rating on shares of Replimune Group in a report on Monday, April 13th. Weiss Ratings raised shares of Replimune Group from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 20th. Finally, BMO Capital Markets raised shares of Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 target price for the company in a research report on Tuesday, June 30th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Replimune Group currently has an average rating of “Moderate Buy” and a consensus price target of $12.86.

Replimune Group Stock Performance

The company has a current ratio of 4.79, a quick ratio of 4.79 and a debt-to-equity ratio of 0.63. The company’s 50 day moving average is $10.15 and its 200-day moving average is $7.54. The company has a market capitalization of $1.01 billion, a P/E ratio of -3.57 and a beta of 0.88.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Monday, June 29th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.10). Equities analysts anticipate that Replimune Group, Inc. will post -2.54 EPS for the current fiscal year.

Insider Buying and Selling at Replimune Group

In related news, insider Christopher Sarchi sold 12,000 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $9.24, for a total transaction of $110,880.00. Following the completion of the transaction, the insider owned 180,962 shares of the company’s stock, valued at $1,672,088.88. This trade represents a 6.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Replimune Group

Hedge funds have recently bought and sold shares of the company. International Assets Investment Management LLC purchased a new position in Replimune Group in the fourth quarter worth about $29,000. Russell Investments Group Ltd. grew its holdings in shares of Replimune Group by 3,638.9% during the third quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock valued at $33,000 after buying an additional 7,569 shares during the last quarter. CWM LLC increased its position in shares of Replimune Group by 248.6% during the fourth quarter. CWM LLC now owns 4,047 shares of the company’s stock valued at $39,000 after acquiring an additional 2,886 shares in the last quarter. Essential Partners LLC increased its position in shares of Replimune Group by 562,400.0% during the first quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock valued at $43,000 after acquiring an additional 5,624 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in Replimune Group by 99.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company’s stock worth $58,000 after acquiring an additional 6,873 shares during the last quarter. Institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.